API
< Back to all clusters
[HEALTH] · United States · 22 sources

started · updated

FDA panel recommends approval for Grail’s Galleri cancer blood test

An FDA advisory panel has recommended the approval of Grail Inc.’s Galleri test, a multi-cancer early detection blood test designed to screen adults aged 50 and older. In a recent meeting, the Molecular and Clinical Genetics Devices Panel voted 7-2, with one abstention, that the potential benefits of the test outweigh its risks. The panel also reached a unanimous 10-0 decision regarding the test’s safety.

However, experts remained divided on the test’s effectiveness, with a 6-4 vote indicating split opinions on whether there is reasonable assurance of its clinical efficacy. While the test identifies cancer-specific methylation patterns in cell-free DNA to signal the presence of tumors, some committee members expressed concerns that current data does not definitively prove it reduces cancer mortality or qualifies as a true “early detection” tool.

If the FDA grants final approval, the test could see widespread adoption and coverage by Medicare and private insurers. Currently, the test is available in the U.S. for out-of-pocket purchase. The FDA is not legally bound by the panel’s recommendation and is expected to make a final decision in the coming months.

Entities

FDA · Food and Drug Administration · Galleri · Grail Inc. · Molecular and Clinical Genetics Devices Panel · U.S. Food and Drug Administration · United States

Claims

What the coverage asserts, and how many sources carry each claim.

Sources